Trial reportBMC infectious diseases2026
Possible effect of neutropenia on the efficacy of artemisinin-based combination therapy in pregnant women in Mali.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReducing the burden of malaria in pregnant women remains a major challenge for control programmes. Decreasing immunity may increase the vulnerability of pregnant women to infectious diseases, including malaria. In this study, the effects of neutropenia on the effectiveness of artemisinin-based combination therapy (ACTs) in clearing current Plasmodium falciparum infections and preventing reinfection after treatment were investigated.
methodsData for this study were obtained within the context of a clinical trial evaluating the efficacy of pyronaridine-artesunate compared with other ACTs for treating malaria infection in pregnant African women. The participants were treated with artemether-lumefantrine (AL, n = 188), dihydroartemisinin-piperaquine (DP, n = 183), or pyronaridine-artesunate (PA, n = 174) and were followed for 63 days after treatment. The dynamics of neutrophil percentages in the peripheral blood of participants were measured during the 63-day follow-up. Pregnant women were classified as either neutropenic or nonneutropenic on the basis of their neutrophil counts at enrolment. A chi-square test was used to compare adequate clinical and parasitological response (ACPR) on Day 28 in the different treatment groups according to neutrophil status.
resultsWithout molecular correction on Day 28, the rate of ACPR was significantly greater in nonneutropenic pregnant women (96.6%; 54/56) than in neutropenic pregnant women (87.0%; 114/131) in the AL arm (p = 0.038). In contrast, ACPR did not vary significantly according to neutrophil status in the DP or PA treatment arms. In the DP treatment arm, ACPR was 97.2% (105/108) and 98.6% (73/74) in neutropenic and nonneutropenic pregnant women, respectively (p = 0.463). In the PA treatment arm, it was 99.1% (105/106) versus 98.5% (66/67) in neutropenic and nonneutropenic pregnant women, respectively (p = 0.851). Molecular analysis revealed that there was no recrudescence during the 28-day follow-up, regardless of the treatment arm.
conclusionThe findings suggest that the prophylactic efficacy of AL, but not of DP or PA, is decreased in neutropenic pregnant women.
trial registrationThe study was registered with the Pan African Clinical Trial Registry (PACTR202011812241529) on 30 November 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.